NAS10026,944+1.18%S&P7,385+0.42%GOLD$4,067−1.12%BTC$75,586−0.47%VIX25.28−10.29%latest tape · as of 18:01 UTC
The Screen · Healthcare · Medical Care Facilities
Addus HomeCare Corporation
ADUS · Nasdaq · USD · Market cap $2.4B · 5,982 employees
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the…
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.45, read 2026-11-05
Ethical passes the values gate
Price126.81 USD
Fair value151.63
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-26Read Accumulation117.95+7.5% to today ✓Markdown gives way to Accumulation first Accumulation read since July
2026-09-19Read Markdown118.51+7.0% to today Markup gives way to Markdown
2026-08-20Read Markup118.06+7.4% to today ✓Accumulation gives way to Markup with volume flow in agreement
2026-07-20Read Accumulation114.52+10.7% to today ✓Distribution gives way to Accumulation after a 23% rise in 3 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Addus HomeCare Corporation holds its Accumulation at $126.81. Consolidating, no directional conviction, held for 152 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 152 days
Price at the screen
$126.81
Valuation
22.41 trailing · 16.93 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.74
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
11.92%
Below 33%
Interest-bearing debt is just 11.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
16.23%
Below 49%
Money owed to the company is 16.2% of assets, under the 49% limit.
Pass
Revenue purity
0.17%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Addus HomeCare clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 12%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ADUS's ethical verdict changes
Today ADUS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 16% discount to our $151.63 fair value, 8.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 16.4% discount to the base estimate.
Where our models see it going: fair-value estimate $151.63, with a range of $124.70 to $207.83, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Home care for the elderly sounds steady yet thin
Imagine an 85 year old needing help to stay at home instead of moving into a facility. Addus supplies that personal care across the United States and clears our ethical screen without issue. The business is growing revenue at 8 percent a year, yet forward earnings sit on a 15.3 times multiple while returns on equity reach only 9 percent and profit margins hold at 7 percent.
We pass because the numbers show a plain service business without a visible moat or standout returns. Analyst targets cluster around 135 dollars against our own fair value of 149 dollars, yet the opportunity rating remains none. Modest growth and average profitability do not create a compelling case once the ethical box is ticked.
Reimbursement rates from government payers can tighten without warning and competition from bigger healthcare groups adds pressure. Low margins leave scant buffer if costs rise or volumes slip. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ADUS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Accumulation$125.75+0.2%Entry 19
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$125.54+0.0%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$125.54+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$125.54+1.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$124.34+1.8%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$122.18+3.6%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$117.95+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$117.95+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133.
2026-10-19Markdown$116.49+1.9%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (13 analysts) rates it buy, with a mean price target of $133.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
